Stocktoria
Universe Pharmaceuticals INC UPC
Universe Pharmaceuticals INC (UPC) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $17.9B at a -20.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.34 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.583 |
| Retained earnings / assets | -0.2 |
| EBIT / assets | -0.042 |
| Equity / liabilities | 4.261 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| UPC | Universe Pharmaceuticals INC | 4/9 | 7.37 | — | -22.4% |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | 7/9 | -0.41 | 84.8 | +4.3% |
| REGN | REGENERON PHARMACEUTICALS, INC. | 5/9 | 9.21 | 14.7 | +1% |
| VTRS | Viatris Inc | 3/9 | 0.65 | — | -3% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | 4/9 | 7.5 | 29.1 | +8.9% |
| BHC | Bausch Health Companies Inc. | 7/9 | -0.26 | 17.8 | +6.7% |
| ZTS | Zoetis Inc. | 5/9 | — | 12.4 | +2.3% |
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
FAQ
Is UPC financially healthy?
Universe Pharmaceuticals INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does UPC pay a dividend?
No, Universe Pharmaceuticals INC does not currently pay a dividend.
How profitable is UPC?
In FY2025, Universe Pharmaceuticals INC had a net margin of -20.6% and a return on equity of -6.5%.
Is UPC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Universe Pharmaceuticals INC: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.